# Firicabtagene autoleucel

Source: https://onco.cc/drugs/firicabtagene-autoleucel/  
OnCo record `firicabtagene-autoleucel` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Firicabtagene autoleucel is an autologous CAR T-cell therapy from CARGO Therapeutics that reached phase 2 for relapsed or refractory large B-cell lymphoma; development has stopped.

## Summary

Firicabtagene autoleucel (CRG-022, firi-cel) is an autologous CAR T-cell therapy from CARGO Therapeutics, with Stanford as ran the phase 1 trial with its formulation of CRG-022. Autologous T cells engineered with a chimeric antigen receptor against CD22. Its furthest stage is phase 2, for relapsed or refractory large B-cell lymphoma. ClinicalTrials.gov registers it in one study linked below. CARGO elected to discontinue the phase 2 FIRCE-1 study on 28 January 2025 (Q1 2025 10-Q); the registry lists NCT05972720 as terminated: "Company decision to stop trial, withdraw the IND and close down operations." Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Also known as: CRG-022; firi-cel
- Tags: pipeline; ctgov-ingest; discontinued
- Code: CRG-022
- Modality: Autologous CAR T-cell therapy
- Mechanism: Autologous T cells engineered with a chimeric antigen receptor against CD22.

## Sources

- CARGO Therapeutics: sec.gov: https://www.sec.gov/Archives/edgar/data/1966494/000095017025066940/crgx-20250331.htm
- CARGO Therapeutics: sec.gov: https://www.sec.gov/Archives/edgar/data/1966494/000095017025066940/crgx-20250331.htm
- CARGO Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT05972720
- ClinicalTrials.gov: trials of CRG-022: https://clinicaltrials.gov/search?intr=CRG-022

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- targets: [CD22](https://onco.cc/targets/cd22/)
- companies: [CARGO Therapeutics](https://onco.cc/companies/cargo-therapeutics/)
- trials: [A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma](https://onco.cc/trials/nct05972720/)

---
JSON: https://onco.cc/api/v1/entities/firicabtagene-autoleucel.json